InsidersTradesSigma
Total declarations
Company
▲ Purchases (14 ops.)
▼ Sales (0 ops.)
Explore the complete record of transactions filed by Cearnal Martin E. Director active across 1 companies, notably Cumberland Pharmaceuticals INC. Cumulatively, 17 reports have been recorded. Total volume traded: €4k. The latest transaction was disclosed on 17 March 2022 — J. Regulator: SEC (Form 4). The full history is free.
Declarations17 total
€37,28915,000 shares@ €2.48590.045% mcap65.4% of flow
Common Stock
SEC:0001209191-22-026154:0·
€32990 shares@ €3.65390.0004% mcap3.3% of flow
Common Stock
SEC:0001209191-22-002447·
Ideal exit: 28 Aug 2022 (T+270)
€32990 shares@ €3.65390.0004% mcap0.6% of flow
Common Stock
SEC:0001209191-22-002447:0·
Ideal exit: 28 Aug 2022 (T+270)
€243105 shares@ €2.31040.0003% mcap2.5% of flow
Common Stock
SEC:0001209191-21-067878·
Ideal exit: 29 Jul 2022 (T+270)
€243105 shares@ €2.31040.0003% mcap0.4% of flow
Common Stock
SEC:0001209191-21-067878:0·
Ideal exit: 29 Jul 2022 (T+270)
€244105 shares@ €2.32410.0003% mcap2.5% of flow
Common Stock
SEC:0001209191-21-063217·
Ideal exit: 28 Jun 2022 (T+270)
€244105 shares@ €2.32410.0003% mcap0.4% of flow
Common Stock
SEC:0001209191-21-063217:0·
Ideal exit: 28 Jun 2022 (T+270)
€255105 shares@ €2.43220.0003% mcap2.6% of flow
Common Stock
SEC:0001209191-21-058506·
Ideal exit: 29 May 2022 (T+270)
€255105 shares@ €2.43220.0003% mcap0.4% of flow
Common Stock
SEC:0001209191-21-058506:0·
Ideal exit: 29 May 2022 (T+270)
€295105 shares@ €2.81270.0004% mcap3.0% of flow
Common Stock
SEC:0001209191-21-055478·
Ideal exit: 29 Apr 2022 (T+270)
€295105 shares@ €2.81270.0004% mcap0.5% of flow
Common Stock
SEC:0001209191-21-055478:0·
Ideal exit: 29 Apr 2022 (T+270)
€259105 shares@ €2.47120.0003% mcap2.6% of flow
Common Stock
SEC:0001209191-21-051433·
Ideal exit: 27 Mar 2022 (T+270)
€259105 shares@ €2.47120.0003% mcap0.5% of flow
Common Stock
SEC:0001209191-21-051433:0·
Ideal exit: 27 Mar 2022 (T+270)
€250105 shares@ €2.38060.0003% mcap2.5% of flow
Common Stock
SEC:0001209191-21-046210·
Ideal exit: 12 Feb 2022 (T+270)
€250105 shares@ €2.38060.0003% mcap0.4% of flow
Common Stock
SEC:0001209191-21-046210:0·
Ideal exit: 12 Feb 2022 (T+270)
€7,9682,945 shares@ €2.70550.0097% mcap80.9% of flow
Common Stock
SEC:0001209191-21-038980·
€7,9682,945 shares@ €2.70550.0097% mcap14.0% of flow
Common Stock
SEC:0001209191-21-038980:0·
17 of 17 declarations
About Cearnal Martin E
Cearnal Martin E is an executive at Cumberland Pharmaceuticals Inc.
